Breast Cancer Research and Treatment · 2023 · 14 citations · 19 references
MedicineOncologyPathologyBreast OncologyMolecular OncologySurgical OncologyBreast Cancer OncologyCancer StagingHer2-positive Breast CancerMalignant NeoplasmsBreast Cancer Molecular SubtypesBreast Cancer PrevalenceBreast Cancer PrognosisClinicopathologic FeaturesDiagnostic ImmunohistochemistryDisease-free Survival AnalysisDisease-free Survival AssessmentHer2 Gene Amplification
PURPOSE: HER2 overexpression has a central role in breast cancer carcinogenesis and is associated with poor prognosis if untreated. Lately, identification of HER2-low breast cancer has been proposed to select patients for novel HER2-directed chemotherapy and includes cancers with immunohistochemistry 1 + or 2 + with negative FISH, encompassing approximately 55-60% of all breast carcinomas. In early-stage breast cancer, the prognostic significance of HER2 low-disease is less well understood, with a particular paucity of data evaluating the prevalence and implications of HER2-low status in invasive lobular carcinoma (ILC). METHODS: We evaluated 666 stage I-III ILC tumors from a prospectively maintained institutional database, comparing clinicopathologic features and disease-free survival (DFS) using a multivariable Cox proportional hazards model. RESULTS: HER2-low status was common in this cohort of patients with ILC, but most clinicopathologic features did not differ between HER2-low and HER2-negative cases. However, when adjusting for tumor size, number of positive nodes, ER/PR status, and local therapy received, patients with HER2-low status had worse disease-free survival (DFS) than those with HER2-negative tumors (hazard ratio 2.0, 95% confidence interval 1.0-4.1, p = 0.05). CONCLUSION: This difference in DFS supports the notion that HER2-low and HER2-negative early stage ILC may differ clinically, despite similar clinicopathologic features. Further investigation into the potential benefit of HER2 targeted therapy in HER2-low early-stage breast cancer, and specifically lobular cancer, is warranted to ensure optimal outcomes in this distinct tumor subtype.
19
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Journal of Clinical Oncology · 2018 · 2.5K citations · Full text
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, Robert J. Gray, Della Makower et al. · New England Journal of Medicine · 2018 · 2.4K citations · Full text
Medicine, Endocrinology, Oncology +17
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts et al. · New England Journal of Medicine · 2016 · 2.1K citations · Full text